See more : Regions Financial Corporation (0KV3.L) Income Statement Analysis – Financial Results
Complete financial analysis of Genertec Universal Medical Group Company Limited (UMTAF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genertec Universal Medical Group Company Limited, a leading company in the Financial – Credit Services industry within the Financial Services sector.
- Pembridge Resources plc (PERE.L) Income Statement Analysis – Financial Results
- McDonald’s Corporation (MDO.DE) Income Statement Analysis – Financial Results
- Surgical Science Sweden AB (publ) (SUS.ST) Income Statement Analysis – Financial Results
- Forrester Research, Inc. (FORR) Income Statement Analysis – Financial Results
- China Railway Group Limited (CRWOF) Income Statement Analysis – Financial Results
Genertec Universal Medical Group Company Limited (UMTAF)
About Genertec Universal Medical Group Company Limited
Genertec Universal Medical Group Company Limited, together with its subsidiaries, offers financing and advisory services in the People's Republic of China. It operates in two segments, Finance and Advisory and Hospital Group. The Finance and Advisory segment provides direct finance leasing; sale and leaseback; factoring; operating leases; and advisory services. The Hospital Group segment engages in the provision of medical services; hospital and healthcare management; and import and export trading businesses, as well as trading of medical-related goods. The company is also involved in the provision of medical technology; hospital digitalization, construction, and management services; property management; and medical consulting services. It serves patients, hospitals, medical equipment suppliers, and other public institutions. The company was formerly known as Universal Medical Financial & Technical Advisory Services Company Limited and changed its name to Genertec Universal Medical Group Company Limited in July 2018. Genertec Universal Medical Group Company Limited was founded in 1984 and is headquartered in Beijing, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.42B | 11.57B | 9.57B | 8.24B | 6.75B | 4.30B | 3.42B | 2.71B | 2.20B | 1.56B | 984.02M |
| Cost of Revenue | 9.08B | 7.43B | 5.71B | 4.97B | 3.64B | 1.71B | 1.24B | 965.97M | 884.85M | 619.59M | 0.00 |
| Gross Profit | 4.34B | 4.14B | 3.85B | 3.28B | 3.11B | 2.59B | 2.18B | 1.74B | 1.31B | 937.17M | 984.02M |
| Gross Profit Ratio | 32.35% | 35.79% | 40.26% | 39.74% | 46.10% | 60.29% | 63.65% | 64.34% | 59.69% | 60.20% | 100.00% |
| Research & Development | 35.88M | 48.07M | 25.84M | 16.63M | 13.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.17B | 899.17M | 739.75M | 613.87M | 441.41M | 244.35M | 189.62M | 277.23M | 246.50M | 190.61M | 143.46M |
| Selling & Marketing | 397.17M | 441.60M | 462.01M | 380.39M | 404.59M | 387.25M | 334.20M | 277.25M | 213.93M | 126.30M | 106.87M |
| SG&A | 1.57B | 1.34B | 1.20B | 994.26M | 846.00M | 631.60M | 523.82M | 554.48M | 460.42M | 316.91M | 261.27M |
| Other Expenses | 0.00 | -530.40M | -279.55M | -109.87M | -94.14M | -104.66M | -20.45M | -3.02M | -3.44M | -16.41M | 0.00 |
| Operating Expenses | 1.60B | 8.86B | 6.88B | 5.88B | 4.53B | 2.44B | 1.85B | 1.50B | 1.29B | 945.68M | 565.68M |
| Cost & Expenses | 1.60B | 8.86B | 6.88B | 5.88B | 4.53B | 2.44B | 1.85B | 1.50B | 1.29B | 945.68M | 565.68M |
| Interest Income | 84.13M | 73.96M | 56.70M | 43.55M | 91.31M | 44.55M | 34.35M | 8.52M | 8.77M | 2.48M | 0.00 |
| Interest Expense | 39.05M | 35.32M | 29.13M | 30.56M | 11.98M | 419.00K | 122.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 508.67M | 442.05M | 319.46M | 270.19M | 139.91M | 31.22M | 27.92M | 22.31M | -849.93M | -620.26M | -374.13M |
| EBITDA | 3.41B | 3.18B | 3.04B | 2.67B | 2.36B | 1.89B | 1.60B | 1.23B | -1.40M | 677.00K | 44.21M |
| EBITDA Ratio | 25.44% | -2.53% | -1.61% | -1.01% | -2.94% | -2.27% | -2.31% | 0.65% | 2.29% | -0.59% | 4.49% |
| Operating Income | 11.82B | 2.80B | 2.65B | 2.28B | 2.26B | 1.96B | 1.66B | 1.19B | 849.93M | 620.26M | 374.13M |
| Operating Income Ratio | 88.07% | 24.20% | 27.70% | 27.68% | 33.56% | 45.59% | 48.35% | 43.87% | 38.72% | 39.84% | 38.02% |
| Total Other Income/Expenses | -8.95B | -644.10M | -517.38M | -329.06M | -211.49M | -136.23M | -97.30M | 13.30M | 50.35M | -9.85M | -304.41M |
| Income Before Tax | 2.87B | 2.70B | 2.69B | 2.37B | 2.21B | 1.86B | 1.58B | 1.21B | 900.27M | 611.08M | 418.34M |
| Income Before Tax Ratio | 21.36% | 23.38% | 28.14% | 28.69% | 32.78% | 43.28% | 46.04% | 44.52% | 41.01% | 39.25% | 42.51% |
| Income Tax Expense | 667.14M | 616.76M | 661.34M | 551.10M | 577.47M | 508.38M | 427.78M | 333.64M | 241.75M | 154.44M | 105.61M |
| Net Income | 2.11B | 1.96B | 1.95B | 1.75B | 1.59B | 1.35B | 1.15B | 872.31M | 658.53M | 456.64M | 312.74M |
| Net Income Ratio | 15.73% | 16.94% | 20.36% | 21.19% | 23.54% | 31.48% | 33.55% | 32.20% | 30.00% | 29.33% | 31.78% |
| EPS | 0.95 | 1.00 | 0.99 | 0.96 | 0.87 | 0.79 | 0.67 | 0.51 | 0.44 | 0.51 | 0.51 |
| EPS Diluted | 0.97 | 0.93 | 0.91 | 0.96 | 0.87 | 0.79 | 0.67 | 0.51 | 0.44 | 0.51 | 0.51 |
| Weighted Avg Shares Out | 2.13B | 2.04B | 2.01B | 1.72B | 1.72B | 1.72B | 1.72B | 1.72B | 1.48B | 900.47M | 613.00M |
| Weighted Avg Shares Out (Dil) | 2.08B | 2.08B | 2.04B | 1.72B | 1.72B | 1.72B | 1.72B | 1.72B | 1.48B | 900.47M | 613.00M |
Source: https://incomestatements.info
Category: Stock Reports